[go: up one dir, main page]

CL2015002835A1 - Nuevos derivados de piridina - Google Patents

Nuevos derivados de piridina

Info

Publication number
CL2015002835A1
CL2015002835A1 CL2015002835A CL2015002835A CL2015002835A1 CL 2015002835 A1 CL2015002835 A1 CL 2015002835A1 CL 2015002835 A CL2015002835 A CL 2015002835A CL 2015002835 A CL2015002835 A CL 2015002835A CL 2015002835 A1 CL2015002835 A1 CL 2015002835A1
Authority
CL
Chile
Prior art keywords
pyridine derivatives
new pyridine
new
piridina
aterosclerosis
Prior art date
Application number
CL2015002835A
Other languages
English (en)
Inventor
Tanja Schulz-Gasch
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Didier Rombach
Olivier Gavelle
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015002835A1 publication Critical patent/CL2015002835A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRIDINA; PROCEDIMIENTO DE OBTENCIÓN; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO O PROFILAXIS DEL DOLOR, ATEROSCLEROSIS, DEGENERACION MACULAR PROPIA DE LA VEJEZ, ENTRE OTRAS ENFERMEDADES.
CL2015002835A 2013-03-26 2015-09-23 Nuevos derivados de piridina CL2015002835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26

Publications (1)

Publication Number Publication Date
CL2015002835A1 true CL2015002835A1 (es) 2016-05-20

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002835A CL2015002835A1 (es) 2013-03-26 2015-09-23 Nuevos derivados de piridina

Country Status (34)

Country Link
US (2) US10308659B2 (es)
EP (1) EP2978755B1 (es)
JP (1) JP6500010B2 (es)
KR (1) KR20150135458A (es)
CN (1) CN105121436B (es)
AR (1) AR095721A1 (es)
AU (1) AU2014243190B2 (es)
BR (1) BR112015024272A2 (es)
CA (1) CA2899168A1 (es)
CL (1) CL2015002835A1 (es)
CR (1) CR20150440A (es)
DK (1) DK2978755T3 (es)
EA (1) EA027569B1 (es)
ES (1) ES2661737T3 (es)
HK (1) HK1211938A1 (es)
HR (1) HRP20180371T1 (es)
HU (1) HUE036934T2 (es)
IL (1) IL240496B (es)
LT (1) LT2978755T (es)
MA (1) MA38404B1 (es)
MX (1) MX365921B (es)
MY (1) MY174000A (es)
NO (1) NO2978755T3 (es)
PE (1) PE20151559A1 (es)
PH (1) PH12015501933B1 (es)
PL (1) PL2978755T3 (es)
PT (1) PT2978755T (es)
RS (1) RS56927B1 (es)
SG (1) SG11201507994QA (es)
SI (1) SI2978755T1 (es)
TW (1) TWI628174B (es)
UA (1) UA116239C2 (es)
WO (1) WO2014154612A1 (es)
ZA (1) ZA201505251B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015190316A1 (ja) * 2014-06-09 2017-04-20 住友化学株式会社 ピリジン化合物の製造方法
AU2016368475B2 (en) * 2015-12-09 2021-03-04 F. Hoffmann-La Roche Ag Phenyl derivatives as cannabinoid receptor 2 agonists
PL3481200T3 (pl) * 2016-07-07 2021-05-17 Dow Agrosciences Llc Sposoby wytwarzania 4-alkoksy-3-(acylo lub alkilo)oksypikolinamidów
TW202417417A (zh) * 2017-04-06 2024-05-01 美商富曼西公司 殺真菌之噁二唑
CN110753690B (zh) * 2017-06-20 2023-12-05 豪夫迈·罗氏有限公司 吡啶衍生物
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
CN119161323A (zh) 2018-06-27 2024-12-20 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物
EP3813888A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
WO2020002280A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN112074513B (zh) 2018-06-27 2024-06-14 豪夫迈·罗氏有限公司 作为优先大麻素2激动剂的吡啶和吡嗪衍生物
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
EP4419508A2 (en) * 2021-10-22 2024-08-28 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531520A (ja) * 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
JP5406716B2 (ja) * 2006-08-07 2014-02-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド インドール化合物
EP2211619A1 (en) * 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
MX2014015491A (es) 2012-07-04 2015-03-06 Hoffmann La Roche Nuevos derivados de adamantilo como agonistas del receptor 2 del canabinoide.
LT2928868T (lt) 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
AU2013354113B2 (en) 2012-12-07 2018-03-08 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as CB2 agonists
IN2015DN03145A (es) 2012-12-07 2015-10-02 Hoffmann La Roche
SG10201800170YA (en) 2012-12-07 2018-02-27 Hoffmann La Roche Novel pyridine derivatives
MX363727B (es) 2013-03-07 2019-04-01 Hoffmann La Roche Nuevos derivados de pirazol.
AU2015239537B2 (en) 2014-04-04 2019-04-04 Eidgenoessische Technische Hochschule Zuerich 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists
SG11201608108SA (en) 2014-04-04 2016-10-28 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists

Also Published As

Publication number Publication date
EP2978755B1 (en) 2018-01-03
TWI628174B (zh) 2018-07-01
EA201591567A1 (ru) 2016-01-29
EP2978755A1 (en) 2016-02-03
KR20150135458A (ko) 2015-12-02
US20160016968A1 (en) 2016-01-21
CN105121436B (zh) 2018-07-27
JP6500010B2 (ja) 2019-04-10
PH12015501933A1 (en) 2016-01-11
TW201518287A (zh) 2015-05-16
US10308659B2 (en) 2019-06-04
MX2015013629A (es) 2016-02-18
PT2978755T (pt) 2018-02-26
AU2014243190A1 (en) 2015-07-30
JP2016516737A (ja) 2016-06-09
MX365921B (es) 2019-06-20
UA116239C2 (uk) 2018-02-26
SI2978755T1 (en) 2018-03-30
RS56927B1 (sr) 2018-05-31
AU2014243190B2 (en) 2018-07-19
NO2978755T3 (es) 2018-06-02
PE20151559A1 (es) 2015-11-05
DK2978755T3 (en) 2018-03-05
SG11201507994QA (en) 2015-10-29
IL240496B (en) 2019-03-31
BR112015024272A2 (pt) 2017-07-18
ES2661737T3 (es) 2018-04-03
CN105121436A (zh) 2015-12-02
MA38404B1 (fr) 2017-09-29
HRP20180371T1 (hr) 2018-04-06
MY174000A (en) 2020-03-03
EA027569B1 (ru) 2017-08-31
US20190248803A1 (en) 2019-08-15
CR20150440A (es) 2015-10-08
CA2899168A1 (en) 2014-10-02
HUE036934T2 (hu) 2018-08-28
MA38404A1 (fr) 2017-01-31
WO2014154612A1 (en) 2014-10-02
IL240496A0 (en) 2015-09-24
ZA201505251B (en) 2016-07-27
AR095721A1 (es) 2015-11-04
HK1211938A1 (en) 2016-06-03
PL2978755T3 (pl) 2018-05-30
LT2978755T (lt) 2018-03-12
PH12015501933B1 (en) 2018-12-14

Similar Documents

Publication Publication Date Title
CL2015002835A1 (es) Nuevos derivados de piridina
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX378273B (es) Compuestos activos hacia bromodominios.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CL2015002387A1 (es) Nuevos derivados de pirazol.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
CL2015003442A1 (es) Derivados heterociclicos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015002897A1 (es) Inhibidores de bace1
MX376113B (es) Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.